Search results
Results From The WOW.Com Content Network
The phase III trial CHRONOS-3 compares copanlisib + rituximab with placebo + rituximab in patients with relapsed iNHL. Study completion is expected for January 2023. [ 35 ] Preliminary results show a strong and significant improvement of progression-free survival under copanlisib treatment, but also considerably more severe and serious side ...
PI3K activation phosphorylates and activates AKT, localizing it in the plasma membrane. [1] AKT can have a number of downstream effects such as activating CREB , [ 2 ] inhibiting p27 , [ 3 ] localizing FOXO in the cytoplasm, [ 3 ] activating PtdIns -3ps, [ 4 ] and activating mTOR [ 3 ] which can affect transcription of p70 or 4EBP1. [ 3 ]